Health Catalyst, Inc. (NASDAQ:HCAT) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Adam Brown - IR Dan Burton - CEO Bryan Hunt - CFO Conference Call Participants Anne Samuel - JPMorgan Ryan Daniels - William Blair Jessica Tassan - Piper Sandler Cindy Motz - Goldman Sachs Elizabeth Anderson - Evercore Stephanie Davis - SVB Securities Richard Close - Canaccord Genuity John Ransom - Raymond James Daniel Grosslight - Citi David Larsen - BTIG Dev Weerasuriya - Berenberg Operator Go ...

Health Catalyst, Inc. (NASDAQ:HCAT) Q4 2021 Earnings Conference Call March 1, 2022 5:00 PM ET Company Participants Adam Brown - IR Dan Burton - CEO Bryan Hunt - CFO Conference Call Participants Ryan Daniels - William Blair Jessica Tassan - Piper Sandler Cindy Motz - Goldman Sachs Elizabeth Anderson - Evercore ISI Stephanie Davis - SVB Leerink Richard Close - Canaccord Genuity John Ransom - Raymond James David Grossman - Stifel Glen Santangelo - Jefferies Operator Good day and thank you for standing by. Welc ...

Health Catalyst, Inc. (NASDAQ:HCAT) Q3 2021 Earnings Conference Call November 9, 2021 5:00 PM ET Company Participants Adam Brown - Investor Relations Dan Burton - Chief Executive Officer Bryan Hunt - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Jessica Tassan - Piper Sandler Stephanie Davis - SVB Leerink David Grossman - Stifel Daniel Grosslight - Citi Thomas Keller - RBC Capital Markets Iris Long - Berenberg David Larsen - BTIG Operator Thank you for standing by and welcome t ...

Health Catalyst, Inc. (NASDAQ:HCAT) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Company Participants Adam Brown - Senior Vice President, Investor Relations & Financial Planning & Analysis Dan Burton - Chief Executive Officer Bryan Hunt - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Ryan Daniels - William Blair Sean Wieland - Piper Sandler Elizabeth Anderson - Evercore Stephanie Davis - SVB Leerink Richard Close - Canaccord Genuity John Ransom - Raymond James Dav ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2021 was $55.8 million, representing a 24% increase year-over-year [10][29] - Adjusted EBITDA for Q1 2021 was a loss of $0.8 million, an improvement from a loss of $6 million in Q1 2020 [10][34] - Adjusted gross margin for Q1 2021 was 54.3%, an increase of 540 basis points year-over-year [10][32] - Adjusted net loss per share in Q1 2021 was $0.06, with approximately 43.9 million shares used in the calculation [35] Business Line Data and Key Metrics Changes - Technology revenue for Q1 2021 was $33.8 million, reflecting a 37% growth year-over-year, driven by new client additions and higher fees from existing clients [10][30] - Professional services revenue for Q1 2021 was $22 million, representing an 8% growth year-over-year [31] - Adjusted technology gross margin for Q1 2021 was 69.1%, an increase of 40 basis points year-over-year [32] - Adjusted professional services gross margin for Q1 2021 was 31.5%, an increase of 660 basis points year-over-year [33] Market Data and Key Metrics Changes - The operating environment remains affected by the COVID-19 pandemic, with both headwinds and tailwinds impacting growth [23][24] - The company anticipates continued operational and financial strain in the provider end market due to the pandemic [24] - There is an expectation of a meaningful consolidation opportunity in the applications layer of the solution stack [26] Company Strategy and Development Direction - The company aims to enable clients to achieve measurable improvements while maintaining high satisfaction levels [12][20] - There is a focus on expanding existing client relationships and beginning new ones, with a strong emphasis on data and analytics solutions [23][25] - The company has over $265 million in cash and short-term investments available for acquisitions, indicating a proactive approach to growth through consolidation [26][131] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the pace of vaccine rollout and its potential to serve as a tailwind for the industry [25] - There is a recognition of the need for commercial-grade data and analytics solutions, which has been highlighted by the pandemic [25] - The company expects total revenue for the full year 2021 to be between $228.1 million and $231.1 million, reflecting a positive outlook [38][39] Other Important Information - The company achieved certification for information security by HITRUST, emphasizing its commitment to data protection [22] - Dr. Tim Ferris concluded his service on the Board, with Jack Kane appointed as the new Chair [27][28] Q&A Session Summary Question: Professional services mix improvement - Management noted an uptick in higher-margin professional services in Q1, with expectations for normalization in the remainder of the year [46][47] Question: Technology growth expectations - Management expects continued robust technology growth for 2021, similar to the previous year’s growth rate of approximately 30% [51] Question: Demand for value-based care - There has been an increase in discussions around population health and value-based care, indicating a shift back to these topics post-COVID [53][80] Question: Nonrecurring services impact - Nonrecurring services contributed approximately $1 million in Q1, but this is a small portion of overall services [69] Question: M&A pipeline and strategy - The company has a robust pipeline for acquisitions, focusing on the applications layer and aiming to strengthen its offerings in areas like population health [128][130]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38993 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter ...

| --- | --- | --- | --- | --- | --- | --- | |-----------------------|-------|-------|---------------|-------|-------------|---------------| | | | | | | | | | HealthCatalyst | | | | | | | | | | | | | | | | | | | | | | | | Overview Presentation | | | | | | 1 4 5 . 2 2 4 | | | | | | | | | | | | | 6 6 2 . 3 5 7 | 8 2 7 | 4 5 . 1 3 3 | | | March 2021 | | | | | | 8 6 . 5 2 | Disclaimer This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than s ...

Health Catalyst, Inc. (HACT) Q4 2020 Earnings Conference Call February 25, 2021 5:00 PM ET Company Participants Adam Brown - SVP, Investor Relations Dan Burton - Chief Executive Officer Bryan Hunt - Chief Financial Officer Conference Call Participants Robert Jones - Goldman Sachs Elizabeth Anderson - Evercore Stephanie Davis - SVB Leerink Richard Close - Canaccord John Ransom - Raymond James David Grossman - Stifel Daniel Grosslight - Citi Glen Santangelo - Guggenheim Securities Iris Long - Berenberg Capita ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________ Form 10-K _______________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents For the transition period from _____ to _____ Commission File Number: 001-38993 HEALTH CATALYST, INC. (Exact name of registrant as specified in its ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2020 was $47.2 million, with $46.3 million excluding the one-month contribution from the Vitalware acquisition, representing an 18% year-over-year increase [9][45] - Total technology revenue for Q3 2020 was $28 million, or $27.2 million excluding Vitalware, reflecting a 28% growth compared to the same period last year [10][46] - Adjusted gross margin for Q3 2020 was 50.7%, an increase of approximately 170 basis points from Q2 2020, but a decrease of about 300 basis points year-over-year [11][48] - Adjusted EBITDA for Q3 2020 was a loss of $6.4 million, an improvement from a loss of $8.4 million in Q3 2019 [11][52] - Cash and cash equivalents at the end of Q3 2020 were $275 million, up from $228 million at the end of 2019 [54] Business Line Data and Key Metrics Changes - Professional services revenue for Q3 2020 was $19.2 million, representing a 5% growth year-over-year, driven by services provided to new customers and expanded services with existing customers [47] - Adjusted gross margin for professional services was 25.1%, a decrease of approximately 1150 basis points year-over-year [50] Market Data and Key Metrics Changes - The company noted a 40% increase in the usage of foundational analytics applications since the onset of the COVID-19 pandemic [21] - The recurring revenue model accounts for over 90% of total revenue, which has helped mitigate the near-term impact of COVID-19 on top-line performance [20] Company Strategy and Development Direction - The company is focused on leveraging the COVID-19 pandemic as a tailwind for the adoption of data and analytics in healthcare [26][110] - Recent acquisitions, including Vitalware, Healthfinch, and Able Health, are expected to enhance the company's product offerings and market reach [28][99] - The introduction of a new President role aims to oversee growth functions and drive international expansion [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the healthcare provider ecosystem's preparedness to respond to ongoing pandemic challenges [18] - The company anticipates a slower revenue growth rate of approximately 20% in 2021 due to the impact of COVID-19 on 2020 bookings [60][61] - Management emphasized the importance of data and analytics in the current environment, which is expected to drive future growth [84][110] Other Important Information - The company announced leadership promotions, including Patrick Nelli to President and Bryan Hunt to Chief Financial Officer, effective January 1, 2021 [30][36] - The company plans to continue investing in M&A opportunities, leveraging its strong cash position [97] Q&A Session Summary Question: Thoughts on 2021 new DOS adds and pipeline performance - Management noted that the second half of 2020 pipeline performance is similar to pre-COVID levels, but the impact of COVID-19 on new customer additions is still a concern [68][71] Question: International expansion opportunities - The company signed its first Middle East customer and is cautiously optimistic about future international growth, though it may take time to see material impacts [73][74] Question: Margins and revenue growth dynamics - Management expects technology revenue to grow faster than professional services revenue, which will positively impact overall gross margins [76][77] Question: Contribution from recent acquisitions - Vitalware contributed approximately $900,000 in Q3 and is expected to contribute around $4 million in Q4, with a projected $20 million impact in 2021 [78][99] Question: Professional services revenue outlook - Management indicated that professional services dollar-based net retention is expected to be lower than historical levels due to COVID-19, but technology revenue retention remains strong [104][105] Question: Role in vaccine distribution - The company anticipates providing analytics support for vaccine distribution, leveraging existing infrastructure [89]